90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

90Y-ibritumomab Tiuxetan in B-cell Non-Hodgkin Lymphomas: Real-world Data From the United Arab Emirates

Purpose: B-cell non-Hodgkin lymphomas (NHLs) are significant contributors to cancer-related mortality. In this single-arm, retrospective cohort study, we aimed to examine the outcomes of a radioimmunotherapeutic modality, 90Y-labeled ibritumomab tiuxetan (90YIT) in B-cell NHLs. Methods and Materials...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Zsolt Szakács, MD, PhD, Amar Lal, MD, Jorgen Kristensen, MD, PhD, Nelli Farkas, PhD, Zsombor Ritter, MD, Szabolcs Kiss, MD, Hussain Alizadeh, MD, PhD, Anett Balikó, MD
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Elsevier 2022-09-01
Cyfres:Advances in Radiation Oncology
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2452109421002402

Rhyngrwyd

http://www.sciencedirect.com/science/article/pii/S2452109421002402

Eitemau Tebyg